Lisa Rosenbaum, M.D .: Transitional Chaos or Enduring Harm? The EHR and the Disruption of Medicine A decade ago, a primary care physician We admired appeared to come undone. His effectiveness had derived not from rushing between sufferers but from knowing them so well that his charting was effortless and fast. But he became distracted instantly, losing his grip on the facts of his individuals’ lives. He slumped around, shirt half-untucked, perpetually pulling a yellowed handkerchief from his pocket to clean his perspiring forehead.

The Wall Road Journal: Hepatitis C Tablet Rockets Gilead Into Big Leagues For decades, a liver disease that could slowly kill the contaminated person didn't have even a name, let alone an effective medicine. Now, a fresh pill promising to remedy most situations of the disease, eventually called hepatitis C, is thought to be the biggest new drug start ever, catapulting maker Gilead Sciences Inc. 13 percent in to the ranks of the top-selling pharmaceutical businesses . Bloomberg: Patient Cures Spur Demand For $1,000 Hepatitis C Tablet The powerful new hepatitis C medication that delivered Gilead Sciences Inc. 's sales soaring last one fourth is doing the same for the hopes of an incredible number of patients. Sandra Cabrera and Ted Tabor both experienced devastating harm from hepatitis C.